Open-Label Study of Intravitreal ICON-1 in Patients With Choroidal Neovascularization Secondary to Age-related Macular Degeneration (AMD)

Stopped early · Phase 2

Conditions studied: Choroidal Neovascularization, Wet Macular Degeneration

In brief

The purpose of this study is to evaluate the safety and effects of repeated intravitreal injections of ICON-1 0.6 mg administered as maintenance therapy or in combination with aflibercept in patients with wet macular degeneration.

Key facts

Study ID

NCT03452527

Run by

Iconic Therapeutics, Inc.

People needed

15

Starts

2018-03-26

Expected to finish

2019-04-25

Last updated by the study team

2021-04-13

Who can join

Age: 50 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Males or females of any race, ≥50 years of age
• Active primary CNV secondary to AMD in the study eye

You may not qualify if…

• Any prior treatment of CNV or advanced AMD in the study eye, except for dietary supplements or vitamins
• Any intraocular or ocular surface surgery (including cataract surgery and laser procedures) in the study eye within 3 months
• Vitrectomy in the study eye

Where it is running

• Site 2 — Beverly Hills, California, United States
• Site 8 — Santa Ana, California, United States
• Site 7 — Syracuse, New York, United States
• Site 3 — Ashland, Oregon, United States
• Site 6 — Philadelphia, Pennsylvania, United States
• Site 1 — Austin, Texas, United States
• Site 4 — McAllen, Texas, United States
• Site 5 — San Antonio, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.